Anna J. Lomax

Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial

Georgina V. Long, Victoria Atkinson, Jonathan Cebon et al. · The Lancet Oncology · 2017 · 246 citations · Full text

Standard-dose Pembrolizumab, Medicine, Melanoma +9

Immunotherapy‐induced sarcoidosis in patients with melanoma treated with <scp>PD</scp>‐1 checkpoint inhibitors: Case series and immunophenotypic analysis

Anna J. Lomax, Helen M. McGuire, Catriona M. McNeil et al. · International Journal of Rheumatic Diseases · 2017 · 103 citations

Certainty within uncertainty: a qualitative study of the experience of metastatic melanoma patients undergoing pembrolizumab immunotherapy

David Levy, Haryana M. Dhillon, Anna J. Lomax et al. · Supportive Care in Cancer · 2018 · 67 citations

Clinical Decision-making, Medicine, Melanoma +4

Impact of Primary Tumor Site on Bevacizumab Efficacy in Metastatic Colorectal Cancer

Hui‐Li Wong, Belinda Lee, Kathryn Field et al. · Clinical Colorectal Cancer · 2016 · 53 citations

Bevacizumab Efficacy, Gastrointestinal Oncology, Medicine +8

A supportive care intervention for people with metastatic melanoma being treated with immunotherapy: a pilot study assessing feasibility, perceived benefit, and acceptability

Judith Lacey, Anna J. Lomax, Catriona M. McNeil et al. · Supportive Care in Cancer · 2018 · 43 citations

Oncology, Health Policy, Patient Support +5